ConnectiCare is known as the employer of choice among managed care organizations in Connecticut.
Paul A. Bluestein
Senior Vice President, Chief Medical Officer
ConnectiCare
Farmington, Conn.
The health plan has accepted full responsibility for its DM programs rather than outsourcing them. "Chronic disease management should be a core objective of a managed care organization," he says, "central to its mission and value system."
The health plan received full DM accreditation from the National Committee for Quality Assurance, which Dr. Bluestein says demonstrates that ConnectiCare can provide value and be recognized by a third-party evaluator. "We have proved that even though we are a small, local health plan, we can still operate as though we are national," he says. The plan also received certification for savings measurement validity for all chronic diseases from DMPC and was awarded top honors in 2005 as a "Leading Disease Management Organization" from HIRC.
Dr. Bluestein predicts that DM will adopt a broader definition and move beyond traditional member stratification and instead, focus on members at-risk and emphasize wellness and disease prevention.
Prior to joining ConnectiCare in 1994, Dr. Bluestein was vice president of managed care for NYH Care Network, a subsidiary of New York Hospital, and national medical director and national director of quality improvement for the MetLife Managed Care Services Group. He received both his undergraduate and medical degrees from Temple University.
Why Patient Registries Need to Make the Move From Tactical to Strategic Research Initiatives
September 6th 2022The one-sided, research-oriented approach has to change so patients have ready access to dashboards with their disease histories and pre-visit documents tailored to the patient questions.
Read More
Study: Patients with High Deductible Plans More Likely to Delay Care
September 7th 2021Patients faced with high out-of-pocket costs sometimes delay seeking care for appendicitis or diverticulitis, which can result in higher overall costs, increased risk of mortality, and a worse quality of life.
Read More